Intrinsiqq
AN2 Therapeutics, Inc. logo

AN2 Therapeutics, Inc. Insider Trading

ANTX

Compare
Last 12 months

Insiders bought 12K and sold 406K on the open market.

78% of the selling was scheduled in advance under 10b5-1 plans. See Remarks Joshua M Eizen sold 25K on Jan 6, 14% of their stake, outside a plan.

Net open-market
−395K
1 buy · 12 sales
Under a 10b5-1 plan
78%
of the value sold
Insiders who bought / sold
1 / 6
executives and directors
Last open-market buy
Sep 2026
Sep 1, 2026

Get an email when ANTX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Nov 5No plan
    Joshua M Eizen
    See Remarks · sold 2,826 at $4.22
    12K
    1.3% of stake
  • Sep 910b5-1 plan
    Robin Shane Readnour
    Director · sold 1,108 at avg $6.02
    7K
    0.2% of stake
  • Sep 3 – 810b5-1 plan
    Robin Shane Readnour
    Director · sold 16,119 at avg $6.04
    97K
    2.5% of stake
  • Sep 1No plan
    Sarah Joanne Williams
    Principal Accounting Officer · sold 272 at $5.53
    2K
    0.4% of stake
  • Sep 1
    Margaret M Fitzpatrick
    Director · bought 2,098 at $5.53
    12K
    24% of stake
  • Aug 1710b5-1 plan
    Robin Shane Readnour
    Director · sold 35,402 at avg $6.01
    213K
    5.2% of stake
  • Jul 8No plan
    Joshua M Eizen
    See Remarks · sold 5,945 at $4.17
    25K
    2.8% of stake
  • May 29No plan
    Sarah Joanne Williams
    Principal Accounting Officer · sold 265 at $4.43
    1K
    0.4% of stake
  • Mar 3No plan
    Sarah Joanne Williams
    Principal Accounting Officer · sold 327 at $1.06
    $347
    0.5% of stake
  • Jan 5 – 6No plan
    Lucy Day
    Chief Financial Officer · sold 8,807 at avg $1.01
    9K
    10% of stake
  • Jan 5 – 6No plan
    Stephen David Prior
    Chief Strategy Officer · sold 6,462 at avg $1.00
    6K
    9.9% of stake
  • Jan 5 – 6No plan
    Sanjay Chanda
    Chief Development Officer · sold 9,251 at avg $1.01
    9K
    11% of stake
  • Jan 5 – 6No plan
    Joshua M Eizen
    See Remarks · sold 24,854 at avg $1.00
    25K
    14% of stake
  • Nov 4, 2025No plan
    Joshua M Eizen
    See Remarks · sold 2,819 at $1.14
    3K
    1.6% of stake
  • Nov 4, 2025No plan
    Stephen David Prior
    Chief Strategy Officer · sold 765 at $1.14
    $872
    1.2% of stake
  • Jun 2, 2025
    Eric Easom
    Chief Executive Officer · bought 10,000 at $1.07
    11K
    2.9% of stake
  • May 28, 2025 – May 30, 2025No plan
    Braden Michael Leonard
    Large holder · sold 2,532,000 at avg $1.13
    $2.87M
    44% of stake
  • May 28, 2025No plan
    Braden Michael Leonard
    Large holder · sold 200,000 at $1.09
    218K
    6.2% of stake
  • May 28, 2025
    Margaret M Fitzpatrick
    Director · bought 8,610 at $1.18
    10K
    New position
  • Jan 3, 2025No plan
    Lucy Day
    Chief Financial Officer · sold 2,957 at $1.34
    4K
    8.3% of stake
  • Jan 3, 2025No plan
    Sanjay Chanda
    Chief Development Officer · sold 2,957 at $1.34
    4K
    9.0% of stake
  • Jan 3, 2025No plan
    Stephen David Prior
    Chief Strategy Officer · sold 2,029 at $1.34
    3K
    5.7% of stake
  • Jan 3, 2025No plan
    Joshua M Eizen
    See Remarks · sold 9,663 at $1.34
    13K
    7.6% of stake
  • Dec 6, 2024 – Dec 10, 2024
    Robin Shane Readnour
    Director · bought 60,000 at avg $1.45
    87K
    10% of stake
  • Nov 26, 2024 – Nov 27, 2024
    Robin Shane Readnour
    Director · bought 75,000 at avg $1.41
    106K
    14% of stake
  • Nov 27, 2024
    Joseph S Zakrzewski
    Director · bought 2,000 at $1.40
    3K
    0.4% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ANTX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ANTX

CompareIntrinsic value
FHTXFoghorn Therapeutics Inc.
$1.72-3.37%46
OCULOcular Therapeutix Inc.
$5.57-4.95%10
TNGXTango Therapeutics Inc.
$21.73-4.32%25
PVLAPavella Therapeutics Inc.
$143.21-1.76%40
XERSXeris Biopharma Holdings, Inc.
$16.97+2.11%34
ACADAcadia Pharmaceuticals Inc.
$17.38-1.19%71
PTGXProtagonist Therapeutics Inc.
$121.40-2.11%62
ELANElanco Animal Health Incorporated
$25.74-2.09%46

Held by ETFs

ANTX is in 1 US ETF. The largest of them, with ANTX's weight in each:

Spot a number that looks wrong? Check it in ANTX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing ANTX

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.